SCHEMBL6303294

SCHEMBL6303294

Cc1csc(Oc2ccc(C(=O)NC3CC4CCN(CC4)C3)cc2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 5/20 0.50
USP30 Q70CQ3 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
EZH2 Q15910 1/20 0.39
MMP2 P08253 3/20 0.39
MMP13 P45452 3/20 0.39
ALDH1A1 P00352 1/20 0.39
HRH3 Q9Y5N1 2/20 0.39
MMP12 P39900 1/20 0.38
CYP2C19 P33261 2/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6631814 0.95 CHRNA7 (0.57) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6305841 0.95 CHRNA7 (0.57) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6305844 0.95 CHRNA7 (0.57) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6305818 0.94 CHRNA7 (0.53) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6310757 0.90 CHRNA7 (0.48) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6305443 0.89 CHRNA7 (0.57) CHRNA7USP30MEN1KMT2AMMP2
SCHEMBL6310608 0.86 CHRNA7 (0.47) CHRNA7USP30
SCHEMBL6629598 0.85 CHRNA7 (0.55) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6310510 0.85 CHRNA7 (0.55) CHRNA7USP30L3MBTL1MEN1KMT2A
SCHEMBL6310504 0.85 CHRNA7 (0.55) CHRNA7USP30L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852716-B2 Substituted-aryl compounds for treatment of disease PFIZER INC (US) 2005-02-08 US claimed
EP-1480977-A2 SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-12-01 EP claimed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US claimed
WO-2003070728-A2 AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO claimed
EP-1480977-A2 SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE PHARMACIA & UPJOHN COMPANY (US) 2004-12-01 EP disclosed
US-20030236279-A1 Substituted-aryl compounds for treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed
WO-2003070728-A2 AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236279-A1 Substituted-aryl compounds for treatment of disease NAT1, CYP7A1, CYP7B1 CHRNA7 2937/4885USP30 4046/4885L3MBTL1 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.